Expedition Therapeutics Secures $115M Series B for COPD Therapy
What's the deal? Expedition Therapeutics has raised an oversubscribed $115 million Series B to advance its lead DPP1 inhibitor into Phase 2 trials. The company is backed by Sanofi VenturesDealroom has a profile for this one. Try Dealroom →.
What's the endgame? The funding will propel Expedition's lead candidate through mid-stage testing as a treatment for chronic obstructive pulmonary disease (COPD).
Why it stands out: The round ranks in the 95th percentile among all Series B rounds for US health companies, based on a sample of 3,694 comparable deals. That places it well above the typical raise at this stage.
The signal: A nine-figure Series B for a Phase 2 candidate signals sustained investor appetite for respiratory drug development — and confidence in Expedition's lead asset to reach the clinic.
Read more: Fierce Biotech
Image credit: f097653195018
